Alcohol Withdrawal and Delirium Tremens

• GABA-A receptor downregulation and altered subunit composition: Chronic ethanol exposure leads to persistent reduction in GABA-A receptor-mediated chloride conductance and changes in receptor subunit composition, shifting from α1-containing to α2/α3-containing subunits. This results in reduced sensitivity to GABA and impaired inhibitory neurotransmission. Upon alcohol cessation, reduced GABAergic tone becomes unmasked, allowing unopposed excitatory neurotransmission to manifest clinically. The severity of GABA-A downregulation correlates with withdrawal severity, explaining the spectrum from mild tremors to seizures and delirium.

• NMDA receptor upregulation and enhanced glutamatergic tone: Chronic ethanol suppresses NMDA receptor activity through multiple mechanisms including magnesium channel blockade and reduced glutamate release. The brain compensates by increasing the number of NMDA receptors and their sensitivity to glutamate. Upon alcohol cessation, unopposed glutamatergic activity through these upregulated NMDA receptors produces excitatory symptoms including tremor, seizures, and autonomic hyperactivity. Glutamate-mediated excitotoxicity may cause neuronal injury, contributing to long-term cognitive consequences.

• Adrenergic system hyperactivity: Chronic ethanol suppresses catecholamine synthesis and release through inhibition of tyrosine hydroxylase and reduced dopamine-β-hydroxylase activity. The brain compensates by upregulating α1 and β-adrenergic receptor expression and increasing their coupling to intracellular signaling pathways. Upon alcohol withdrawal, unopposed sympathomimetic activity manifests as tachycardia, hypertension, diaphoresis, tremor, and anxiety. Decreased activity of the inhibitory noradrenergic locus coeruleus feedback system further exacerbates adrenergic dysregulation.

• Altered CRH-ACTH axis and HPA activation: Chronic ethanol directly suppresses corticotropin-releasing hormone (CRH) secretion and hypothalamic-pituitary-adrenal (HPA) axis function. During withdrawal, loss of alcohol's CNS depressant effect unmasks HPA hyperactivity, with elevated CRH, ACTH, and cortisol contributing to anxiety, tremor, and tachycardia. The magnitude of HPA activation correlates with withdrawal severity.

• Ion channel and electrolyte dysfunction: Chronic ethanol and acute withdrawal both produce significant alterations in intracellular calcium handling through effects on L-type and N-type calcium channels. Increased intracellular calcium in withdrawal states exacerbates excitotoxicity. Additionally, acute withdrawal frequently causes hypomagnesemia (through both renal losses and poor intake), and magnesium is critical for blocking NMDA receptors; hypomagnesemia therefore intensifies NMDA-mediated excitotoxicity and predisposes to seizures.

• Immune and inflammatory pathway activation: Acute alcohol withdrawal triggers microglial activation and increased production of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), contributing to neuroinflammation. Lipopolysaccharide (LPS) translocation from dysbiotic gut flora due to alcohol's effects on intestinal permeability activates pattern recognition receptors, perpetuating inflammatory cascades. These inflammatory mediators directly contribute to delirium, autonomic dysregulation, and potential neuronal injury.

• Chronic heavy alcohol consumption with sudden cessation: The absolute defining prerequisite is established physiologic dependence through regular heavy drinking (typically ≥8 drinks/week in women, ≥15 drinks/week in men for ≥2 weeks, though many with severe alcohol use disorder consume vastly more). Abrupt cessation—whether due to hospitalization, incarceration, financial constraints, or deliberate reduction—precipitates withdrawal. The risk is proportional to both the quantity and duration of chronic consumption; individuals consuming >100 grams daily for several years are at particular risk for severe withdrawal.

• Concurrent acute illness and physiologic stress: Superimposed acute medical illness dramatically increases withdrawal severity and risk of progression to delirium tremens and seizures. Infections (pneumonia, UTI, sepsis), hepatic decompensation, acute pancreatitis, GI bleeding, myocardial infarction, and trauma all serve as precipitants. These conditions likely increase withdrawal risk through multiple mechanisms: inflammatory cytokine production, electrolyte disturbances, hypoxia, and altered drug metabolism. Hospitalized patients with concurrent illness represent the highest-risk population.

• Prior severe withdrawal episodes or seizures: A history of previous alcohol withdrawal seizures or delirium tremens is the single strongest predictor of recurrent severe withdrawal. This "kindling" phenomenon suggests progressive neuroadaptation with each withdrawal cycle, possibly reflecting increasingly sensitized glutamatergic and adrenergic systems. Individuals with prior severe withdrawal have markedly increased risk of progression through the severity spectrum.

• Concurrent benzodiazepine or sedative-hypnotic dependence: Polysubstance dependence on benzodiazepines, barbiturates, or other sedatives alongside alcohol dramatically increases withdrawal severity. These agents produce similar GABA-A downregulation, and concurrent cessation of multiple CNS depressants produces compounded excitatory dysregulation. Withdrawal from combined substances may be more severe and protracted than from alcohol alone.

• Electrolyte abnormalities and nutritional deficiencies: Chronic heavy alcohol use produces multiple micronutrient and electrolyte deficiencies (magnesium, phosphate, thiamine, folate, B12). Hypomagnesemia is particularly significant, as magnesium is essential for NMDA receptor blockade; depletion intensifies excitotoxicity. Hypophosphatemia and hypokalemia further destabilize cardiac electrical stability. These deficiencies typically worsen during acute withdrawal and hospitalization, necessitating aggressive repletion.

• Advanced liver disease and hepatic dysfunction: Patients with advanced cirrhosis or portal hypertension have impaired metabolism of benzodiazepines and altered ammonia metabolism, increasing both withdrawal severity and encephalopathy risk. Hepatic encephalopathy can coexist with or mimic delirium tremens, complicating diagnosis and management.

• Increased age and comorbidities: While AWS can occur at any age, older individuals (>65 years) may experience more severe withdrawal despite lower absolute alcohol consumption, likely due to reduced physiologic reserve and altered benzodiazepine metabolism. Comorbidities including cardiac arrhythmias, hypertension, diabetes, and pulmonary disease increase morbidity and mortality from withdrawal complications.

• Tremor and hyperreflexia: Fine postural tremor of the hands, typically beginning 6–12 hours after last drink, represents the most common early manifestation of AWS. The tremor is prominent with arms outstretched and may progress to gross tremor at rest in severe cases. Physiologically, tremor results from unopposed adrenergic and glutamatergic activity affecting cerebellar and basal ganglia circuits. Hyperreflexia with brisk deep tendon reflexes similarly reflects CNS hyperexcitability and appears early in the withdrawal sequence. Assessment of tremor severity using objective measures (ability to hold paper steady, amplitude) provides useful prognostic information.

• Autonomic hyperactivity: Sympathomimetic surge produces tachycardia (heart rate often 100–140 bpm), hypertension (sometimes 150–180 mmHg systolic), tachypnea, and profuse diaphoresis. These findings typically appear within 12 hours of cessation and may persist for days. Patients often describe subjective anxiety, palpitations, and sense of impending doom. The physiologic basis stems from unopposed α and β-adrenergic stimulation and HPA axis activation. Importantly, vital sign abnormalities may be absent in mild withdrawal but are invariably present in moderate-to-severe disease.

• Visual, tactile, and auditory hallucinations: Hallucinations characteristically appear 12–24 hours after last drink in a patient with clear sensorium and oriented mentation (before delirium tremens develops). Visual hallucinations predominate—often described as small animals, insects, or threatening figures—and are frequently accompanied by tactile hallucinations (formication—sensation of insects crawling on skin). Auditory hallucinations are less common but may include threatening voices. Patients often retain insight into the unreality of perceptions in early withdrawal hallucinations ("alcoholic hallucinosis"), distinguishing this from the confused state of delirium tremens. These hallucinations reflect hyperactivity of visual cortex and limbic structures, likely driven by glutamatergic excess and dopaminergic dysregulation.

• Withdrawal seizures: Generalized tonic-clonic seizures occur in 5–15% of patients experiencing AWS, typically beginning 6–48 hours after last drink, with peak incidence around 12–24 hours. Seizures may be single (70%) or multiple (30%), and status epilepticus occurs in 5% of seizing patients. Seizures result from glutamate-mediated excitotoxicity and reduced GABA inhibition in cortical and limbic circuits. Risk increases significantly with prior withdrawal seizures (kindling). Many seizures are brief and patient may seek care only later; therefore, history of unexplained seizures during prior drinking cessation is critical to elicit. Immediately following seizure, patients may appear relatively normal—the seizure itself does not indicate progression to delirium tremens, though seizures and DTs often coexist.

• Delirium tremens (DTs): The hallmark manifestation of severe AWS, DTs typically occurs 48–96 hours after last drink (though may occur as late as 7–10 days). DTs is characterized by the triad of: (1) autonomic hyperactivity (severe tachycardia, hypertension, fever often 38–40°C, profuse diaphoresis), (2) disorientation and delirium (global confusion, inability to recognize place, time, or persons, fluctuating mental status), and (3) vivid hallucinations (visual > tactile > auditory). Psychomotor agitation is nearly universal, with patients pulling at lines, trying to climb out of bed, or exhibiting combative behavior. Autonomic instability may be extreme, with heart rates >150 bpm and blood pressures >200 mmHg. The profound altered mental status and disorientation of DTs distinguishes it from earlier alcoholic hallucinosis. Mortality from untreated DTs historically exceeded 35% but drops to <5% with appropriate benzodiazepine treatment. Death typically results from uncontrolled arrhythmias, seizures, aspiration, or concurrent medical illness.

• Physical examination findings: Beyond vital sign abnormalities and tremor, exam may reveal nystagmus, ataxia, and gait disturbance (from cerebellar dysfunction and vestibular effects). Patients may appear anxious, agitated, or fearful. Stigmata of chronic liver disease (spider angiomas, gynecomastia, palmar erythema, jaundice) suggest advanced hepatic dysfunction. Signs of nutritional deficiency (peripheral neuropathy from thiamine deficiency, oral ulceration, glossitis) may be present. Ophthalmologic findings may include horizontal or vertical nystagmus (from alcohol's vestibulocerebellar effects or Wernicke syndrome).

• Important clinical variants: Hallucinosis without delirium represents a less common variant where auditory or visual hallucinations occur with clear sensorium (patient knows hospital name, date, and persons); prognosis is better than DTs but still requires treatment. Withdrawal-related seizures without progression to DTs occur in some patients—management must still include benzodiazepines given seizure risk. Masked or atypical withdrawal may occur in patients with concurrent severe illness (infection, MI, stroke) where sepsis, infarction, or other conditions predominate clinically while withdrawal simultaneously develops, creating diagnostic difficulty.

• Clinical history and temporal relationship: The critical historical element is establishing both chronic heavy alcohol consumption (quantity, frequency, duration) and recent cessation or significant reduction. Ask specifically: "When was your last drink?" Onset of symptoms within 6–96 hours of cessation strongly supports AWS diagnosis. Obtain collateral history from family, friends, or prior medical records regarding baseline alcohol use pattern. Detailed timeline of symptom progression (tremor → autonomic signs → hallucinations → delirium) supports AWS diagnosis. Prior episodes of withdrawal, seizures, or DTs dramatically increase pretest probability of current withdrawal being severe.

• Physical examination assessment: Carefully assess and document vital signs (heart rate, blood pressure, temperature, respiratory rate) at baseline and serially—progressive tachycardia and hypertension support ongoing withdrawal. Grade tremor severity (0=absent, 1=barely perceptible, 2=noticeable, 3=gross tremor; tremor >grade 1 indicates moderate withdrawal). Perform detailed neurologic exam: sensorium and orientation (disorientation suggests delirium tremens or concurrent illness), presence of hallucinations (ask patient directly: "Are you seeing/hearing things that aren't really there?"), reflexes (hyperreflexia indicates CNS hyperexcitability), and gait assessment. Search for stigmata of liver disease and nutritional deficiency. Reassess exam frequently—progression of symptoms warrants escalation of treatment.

• Clinical scoring systems: The CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol Scale, revised) is the gold-standard validated scoring tool for objectively assessing withdrawal severity and guiding treatment decisions. The CIWA-Ar evaluates: tremor (0–4), sweating (0–4), anxiety (0–4), agitation (0–4), tactile hallucinations (0–4), auditory hallucinations (0–4), visual hallucinations (0–4), headache (0–4), orientation/clouding of sensorium (0–4), and paroxysmal sweats (0–4). Total score ranges from 0–67: scores <10 indicate mild withdrawal requiring observation; 10–20 indicate moderate withdrawal requiring benzodiazepines; >20 indicate severe withdrawal requiring intensive benzodiazepine dosing. The CIWA-Ar should be administered every 1–4 hours during acute withdrawal to guide dosing and detect progression. Sensitivity for detecting clinically significant withdrawal is >95%, making it essential for standardized assessment.

• Laboratory assessment and biomarkers: While no lab test diagnoses AWS specifically, multiple tests serve important purposes in evaluation: (1) Blood alcohol level (BAL)—should be low or undetectable if withdrawal is from prolonged cessation; a detectable BAL suggests ongoing drinking or very recent drinking and argues against withdrawal as explanation for current symptoms; (2) Electrolytes (sodium, potassium, chloride, bicarbonate)—assess for hypokalemia (risk factor for arrhythmias) and hyponatremia (may cause altered mental status

Immediate stabilisation

• Airway, IV access, continuous monitoring: severe withdrawal and DTs belong in a monitored or ICU bed; agitated, hyperthermic patients are at risk for aspiration and arrhythmia.
• Thiamine before glucose: parenteral thiamine precedes any dextrose-containing fluid, since glucose loading in a thiamine-depleted patient consumes the remaining cofactor for transketolase/pyruvate dehydrogenase and can precipitate Wernicke encephalopathy. High-dose IV thiamine is given when Wernicke is suspected.
• Correct electrolytes: repletion of magnesium, potassium, and phosphate. Magnesium restores the voltage-dependent block of NMDA receptors, so hypomagnesemia lowers seizure threshold.

First-line therapy

• Benzodiazepines: the only class that treats the underlying GABA-A deficit and reduces seizures, delirium, and mortality. Long-acting agents (chlordiazepoxide, diazepam) provide a self-tapering effect; lorazepam or oxazepam (glucuronidated only — no phase I oxidation) are preferred in cirrhosis, elderly patients, and respiratory compromise.
• Symptom-triggered dosing guided by CIWA-Ar is preferred by the ASAM 2020 alcohol withdrawal management guideline over fixed-schedule dosing, as it lowers cumulative dose and duration. Fixed-dose or front-loaded regimens are used when CIWA-Ar cannot be scored (intubated, encephalopathic, or non-communicative patients) or when withdrawal risk is very high.

Escalation for benzodiazepine-refractory withdrawal

• Barbiturates: phenobarbital directly opens the chloride channel independent of GABA binding, bypassing benzodiazepine tolerance; ASAM endorses it for refractory cases with airway monitoring.
• Propofol with intubation in the ICU for benzodiazepine- and phenobarbital-refractory DTs.
• Dexmedetomidine (α2 agonist) is an adjunct for autonomic hyperactivity and agitation only — it does not prevent seizures or delirium.

Avoid

• Antipsychotic monotherapy (haloperidol): lowers seizure threshold and prolongs QT — adjunct only.
• Beta blockers/clonidine as sole therapy: blunt vital signs and mask CIWA-Ar scores without preventing seizures or DTs.
• Phenytoin: ineffective for withdrawal seizures.

Complications of the disease

• Status epilepticus (emergency): repetitive withdrawal seizures from unopposed NMDA-mediated excitation; signalled by a second seizure without recovery of consciousness. Treat with benzodiazepines, not phenytoin.
• Delirium tremens (emergency): signalled by disorientation superimposed on autonomic hyperactivity — the transition from alcoholic hallucinosis (clear sensorium) to global confusion.
• Arrhythmias and cardiovascular collapse (emergency): catecholamine surge plus hypokalemia/hypomagnesemia; atrial fibrillation (holiday heart) and QT prolongation with torsades are the signal findings.
• Hyperthermia, rhabdomyolysis, and acute kidney injury: sustained agitation and muscle activity; suspect when CK is markedly elevated with pigmented urine (heme-positive dipstick without RBCs).
• Aspiration pneumonia: depressed sensorium plus seizures; new hypoxemia and infiltrate.
• Wernicke encephalopathy (emergency): thiamine depletion; confusion, ophthalmoplegia/nystagmus, ataxia — untreated it progresses to irreversible Korsakoff amnestic syndrome with confabulation.
• Occult alternative pathology: subdural hematoma, meningitis, hepatic encephalopathy, alcoholic ketoacidosis, and hypoglycemia all mimic or coexist with DTs. Fever or focal neurologic deficit should trigger infectious workup and head imaging rather than attribution to withdrawal alone.
• Refeeding syndrome: carbohydrate load drives intracellular phosphate shift; falling phosphate with arrhythmia or weakness.

Complications of treatment

• Benzodiazepine oversedation and respiratory depression: excessive cumulative dosing, especially with long-acting agents in cirrhosis; signalled by hypercapnia and obtundation. Flumazenil is avoided — it can precipitate refractory seizures.
• Propylene glycol toxicity: from prolonged high-dose IV lorazepam infusions; signalled by an unexplained high anion-gap metabolic acidosis with an elevated osmolar gap and rising creatinine.
• Phenobarbital: hypotension and apnea; requires airway readiness.
• Haloperidol: seizures, QT prolongation, and neuroleptic malignant syndrome (rigidity, hyperthermia, elevated CK) — easily confused with DTs itself.
• Dexmedetomidine: bradycardia and hypotension, and masking of worsening withdrawal.

• Know the clock: tremor/autonomic signs at 6–12 h, alcoholic hallucinosis at 12–24 h, withdrawal seizures at 6–48 h, and delirium tremens at 48–96 h. The timeline in the stem usually gives away the answer.
• Hallucinosis vs. DTs: the discriminator is sensorium, not the hallucination. Hallucinations with intact orientation = alcoholic hallucinosis; hallucinations plus disorientation and fluctuating attention = DTs, a medical emergency.
• Single best next step in any severity: a benzodiazepine, dosed symptom-triggered against CIWA-Ar per ASAM. Antipsychotics, beta blockers, and clonidine are adjuncts and never replace it.
• Liver disease → LOT: lorazepam, oxazepam, temazepam undergo glucuronidation only and lack active metabolites, so they are safest in cirrhosis and in the elderly. Chlordiazepoxide and diazepam accumulate.
• Thiamine before glucose: giving dextrose first can precipitate Wernicke encephalopathy (confusion, ophthalmoplegia, ataxia) — a favorite one-line trap.
• The association examiners test: prior withdrawal seizures or DTs is the strongest predictor of severe recurrence (kindling); hypomagnesemia amplifies NMDA excitotoxicity and lowers seizure threshold.
• Refractory case: escalate to phenobarbital, which opens the chloride channel independently of GABA binding and therefore works despite benzodiazepine tolerance; propofol with intubation is the ICU endpoint.
• Common distractors to avoid: phenytoin does not prevent alcohol withdrawal seizures; haloperidol monotherapy lowers seizure threshold and prolongs QT; flumazenil in an oversedated withdrawal patient can trigger refractory seizures; and fever in a patient with DTs still requires an infection workup rather than reflexive attribution to withdrawal.